Non-CYP metabolism. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Gemcitabine hydrochloride is a synthetic pyrimidine nucleoside.

Gemcitabine is an antimetabolite antineoplastic agent used in combinatiion with other cytostatatics in urine bladder cancer with metastases, advanced breast cancer, lung cancer or advanced ovarial cancer. Administered as an infusion. Common adverse reactions of gemcitabine that can be confused with an acute porphyric attack are nausea, vomiting, diarrhoea or obstipation. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Gemcitabine is a pyrimidine antimetabolite that is rapidly metabolized by cytidine deaminase in the liver, kidneys and blood cells. About 91 - 98 per cent is converted to diphosphate dioxydifluorouridine, which is excreted in urine. Non-CYP metabolism, interactions with CYP-metabolism of other drugs not to be expected.

No.